


AMENDMENTS TO THE CLAIMS

1. **(Currently Amended)** A compound of formula I:



wherein

X^1 , X^2 , X^3 , X^4 , and X^5 are independently selected from the group consisting of C, CR^5 , N, O, and S, wherein at least one of X^1 , X^2 , X^3 , X^4 , and X^5 is not N;

X^6 is selected from the group consisting of a bond and CR^5R^6 ;

X^7 is CR^5 or N;

X^8 is selected from the group consisting of a bond, CR^5R^6 , NR^5 , O, S, SO, and SO_2 ;

X⁹ is CR⁵-or-N;

X¹⁰ is selected from the group consisting of a bond, CR⁵R⁶, (CR⁵R⁶)₂, O, S, and NR⁵;

R¹ is selected from the group consisting of hydroxy, halo, nitro, C₁₋₆alkylhalo, OC₁₋₆alkylhalo, C₁₋₆alkyl, OC₁₋₆alkyl, C₂₋₆alkenyl, OC₂₋₆alkenyl, C₂₋₆alkynyl, OC₂₋₆alkynyl, C₀₋₆alkylC₃₋₆cycloalkyl, OC₀₋₆alkylC₃₋₆cycloalkyl, C₀₋₆alkylaryl, OC₀₋₆alkylaryl, CHO, (CO)R⁵, O(CO)R⁵, O(CO)OR⁵, ~~Θ(CN)ΘR⁵~~, C₁₋₆alkylOR⁵, OC₂₋₆alkylOR⁵, C₁₋₆alkyl(CO)R⁵, OC₁₋₆alkyl(CO)R⁵, C₀₋₆alkylCO₂R⁵, OC₁₋₆alkylCO₂R⁵, C₀₋₆alkylcyano, OC₂₋₆alkylcyano, C₀₋₆alkylNR⁵R⁶, OC₂₋₆alkylNR⁵R⁶, C₁₋₆alkyl(CO)NR⁵R⁶, OC₁₋₆alkyl(CO)NR⁵R⁶, C₀₋₆alkylNR⁵(CO)R⁶, OC₂₋₆alkylNR⁵(CO)R⁶, C₀₋₆alkylNR⁵(CO)NR⁵R⁶, C₀₋₆alkylSR⁵, OC₂₋₆alkylSR⁵, C₀₋₆alkyl(SO)R⁵, OC₂₋₆alkyl(SO)R⁵, C₀₋₆alkylSO₂R⁵, OC₂₋₆alkylSO₂R⁵, C₀₋₆alkyl(SO₂)NR⁵R⁶, OC₂₋₆alkyl(SO₂)NR⁵R⁶, C₀₋₆alkylNR⁵(SO₂)R⁶, OC₂₋₆alkylNR⁵(SO₂)R⁶, C₀₋₆alkylNR⁵(SO₂)NR⁵R⁶, OC₂₋₆alkylNR⁵(SO₂)NR⁵R⁶, (CO)NR⁵R⁶, O(CO)NR⁵R⁶, NR⁵OR⁶, C₀₋₆alkylNR⁵(CO)OR⁶, OC₂₋₆alkylNR⁵(CO)OR⁶, SO₃R⁵ and a 5- or 6-membered ring containing atoms independently selected from the group consisting of C, N, O and S, wherein said ring may be substituted by one or more A;

R² is selected from the group consisting of hydrogen, hydroxy, halo, nitro, C₁₋₆alkylhalo, OC₁₋₆alkylhalo, C₁₋₆alkyl, OC₁₋₆alkyl, C₂₋₆alkenyl, OC₂₋₆alkenyl, C₂₋₆alkynyl, OC₂₋₆alkynyl, C₀₋₆alkylC₃₋₆cycloalkyl, OC₀₋₆alkylC₃₋₆cycloalkyl, C₀₋₆alkylaryl, OC₀₋₆alkylaryl, CHO, (CO)R⁵, O(CO)R⁵,

$O(CO)OR^5$, $\Theta(CN)OR^5$, $C_{1-6}alkylOR^5$, $OC_{2-6}alkylOR^5$, $C_{1-6}alkyl(CO)R^5$, $OC_{1-6}alkyl(CO)R^5$, $C_{0-6}alkylCO_2R^5$, $OC_{1-6}alkylCO_2R^5$, $C_{0-6}alkylcyano$, $OC_{2-6}alkylcyano$, $C_{0-6}alkylNR^5R^6$, $OC_{2-6}alkylNR^5R^6$, $C_{1-6}alkyl(CO)NR^5R^6$, $OC_{1-6}alkyl(CO)NR^5R^6$, $C_{0-6}alkylNR^5(CO)R^6$, $OC_{2-6}alkylNR^5(CO)R^6$, $C_{0-6}alkylNR^5(CO)NR^5R^6$, $C_{0-6}alkylSR^5$, $OC_{2-6}alkylSR^5$, $C_{0-6}alkyl(SO)R^5$, $OC_{2-6}alkyl(SO)R^5$, $C_{0-6}alkylSO_2R^5$, $OC_{2-6}alkylSO_2R^5$, $C_{0-6}alkyl(SO_2)NR^5R^6$, $OC_{2-6}alkyl(SO_2)NR^5R^6$, $C_{0-6}alkylNR^5(SO_2)R^6$, $OC_{2-6}alkylNR^5(SO_2)R^6$, $C_{0-6}alkylNR^5(SO_2)NR^5R^6$, $OC_{2-6}alkylNR^5(SO_2)NR^5R^6$, $(CO)NR^5R^6$, $O(CO)NR^5R^6$, NR^5OR^6 , $C_{0-6}alkylNR^5(CO)OR^6$, $OC_{2-6}alkylNR^5(CO)OR^6$, SO_3R^5 and a 5- or 6-membered ring containing atoms independently selected from the group consisting of C, N, O and S, wherein said ring may be substituted by one or more A;

R^3 is a 5- or 6-membered ring containing atoms independently selected from the group consisting of C, N, O and S, wherein said ring may be substituted by one or more A;

R^4 is selected from the group consisting of hydroxy, halo, nitro, $C_{1-6}alkylhalo$, $OC_{1-6}alkylhalo$, $C_{1-6}alkyl$, $OC_{1-6}alkyl$, $C_{2-6}alkenyl$, $OC_{2-6}alkenyl$, $C_{2-6}alkynyl$, $OC_{2-6}alkynyl$, $C_{0-6}alkylC_{3-6}cycloalkyl$, $OC_{0-6}alkylC_{3-6}cycloalkyl$, $C_{0-6}alkylaryl$, $OC_{0-6}alkylaryl$, CHO , $(CO)R^5$, $O(CO)R^5$, $O(CO)OR^5$, $\Theta(CN)OR^5$, $C_{1-6}alkylOR^5$, $OC_{2-6}alkylOR^5$, $C_{1-6}alkyl(CO)R^5$, $OC_{1-6}alkyl(CO)R^5$, $C_{0-6}alkylCO_2R^5$, $OC_{1-6}alkylCO_2R^5$, $C_{0-6}alkylcyano$, $OC_{2-6}alkylcyano$, $C_{0-6}alkylNR^5R^6$, $OC_{2-6}alkylNR^5R^6$, $C_{1-6}alkyl(CO)NR^5R^6$, $OC_{1-6}alkyl(CO)NR^5R^6$, $C_{0-6}alkylNR^5(CO)R^6$, $OC_{2-6}alkylNR^5(CO)R^6$, $C_{0-6}alkylNR^5(CO)NR^5R^6$, $C_{0-6}alkylSR^5$, $OC_{2-6}alkylSR^5$, $C_{0-6}alkyl(SO)R^5$, $OC_{2-6}alkyl(SO)R^5$, $C_{0-6}alkyl$

$_6\text{alkylSO}_2\text{R}^5$, $\text{OC}_{2,6}\text{alkylSO}_2\text{R}^5$, $\text{C}_{0,6}\text{alkyl}(\text{SO}_2)\text{NR}^5\text{R}^6$, $\text{OC}_{2,6}\text{alkyl}(\text{SO}_2)\text{NR}^5\text{R}^6$, $\text{C}_{0,6}\text{alkylNR}^5(\text{SO}_2)\text{R}^6$,
 $\text{OC}_{2,6}\text{alkylNR}^5(\text{SO}_2)\text{R}^6$, $\text{C}_{0,6}\text{alkylNR}^5(\text{SO}_2)\text{NR}^5\text{R}^6$, $\text{OC}_{2,6}\text{alkylNR}^5(\text{SO}_2)\text{NR}^5\text{R}^6$, $(\text{CO})\text{NR}^5\text{R}^6$,
 $\text{O}(\text{CO})\text{NR}^5\text{R}^6$, NR^5OR^6 , $\text{C}_{0,6}\text{alkylNR}^5(\text{CO})\text{OR}^6$, $\text{OC}_{2,6}\text{alkylNR}^5(\text{CO})\text{OR}^6$, SO_3R^5 and a 5- or 6-
 membered ring containing atoms independently selected from the group consisting of C, N, O
 and S, wherein said ring may be substituted by one or more A;

R^5 and R^6 are independently selected from the group consisting of hydrogen, $\text{C}_{1,6}\text{alkyl}$, $\text{C}_{3,7}\text{cycloalkyl}$ and aryl;

A is selected from the group consisting of hydrogen, hydroxy, halo, nitro, $\text{C}_{1,6}\text{alkylhalo}$, $\text{OC}_{1,6}\text{alkylhalo}$, $\text{C}_{1,6}\text{alkyl}$, $\text{OC}_{1,6}\text{alkyl}$, $\text{C}_{2,6}\text{alkenyl}$, $\text{OC}_{2,6}\text{alkenyl}$, $\text{C}_{2,6}\text{alkynyl}$, $\text{OC}_{2,6}\text{alkynyl}$, $\text{C}_{0,6}\text{alkylC}_{3,6}\text{cycloalkyl}$, $\text{OC}_{0,6}\text{alkylC}_{3,6}\text{cycloalkyl}$, $\text{C}_{0,6}\text{alkylaryl}$, $\text{OC}_{0,6}\text{alkylaryl}$, CHO , $(\text{CO})\text{R}^5$, $\text{O}(\text{CO})\text{R}^5$,
 $\text{O}(\text{CO})\text{OR}^5$, $\Theta(\text{CN})\text{OR}^5$, $\text{C}_{1,6}\text{alkylOR}^5$, $\text{OC}_{2,6}\text{alkylOR}^5$, $\text{C}_{1,6}\text{alkyl}(\text{CO})\text{R}^5$, $\text{OC}_{1,6}\text{alkyl}(\text{CO})\text{R}^5$, $\text{C}_{0,6}\text{alkylCO}_2\text{R}^5$, $\text{OC}_{1,6}\text{alkylCO}_2\text{R}^5$, $\text{C}_{0,6}\text{alkylcyano}$, $\text{OC}_{2,6}\text{alkylcyano}$, $\text{C}_{0,6}\text{alkylNR}^5\text{R}^5$, $\Theta\text{C}_{2,6}\text{alkylNR}^5\text{R}^5$,
 $\text{C}_{1,6}\text{alkyl}(\text{CO})\text{NR}^5\text{R}^8$, $\Theta\text{C}_{1,6}\text{alkyl}(\text{CO})\text{NR}^5\text{R}^8$, $\text{C}_{0,6}\text{alkylNR}^5(\text{CO})\text{R}^8$, $\Theta\text{C}_{2,6}\text{alkylNR}^5(\text{CO})\text{R}^8$, $\text{C}_{0,6}\text{alkylNR}^5(\text{CO})\text{NR}^5\text{R}^8$, $\text{C}_{0,6}\text{alkylSR}^5$, $\text{OC}_{2,6}\text{alkylSR}^5$, $\text{C}_{0,6}\text{alkyl}(\text{SO})\text{R}^5$, $\text{OC}_{2,6}\text{alkyl}(\text{SO})\text{R}^5$, $\text{C}_{0,6}\text{alkylSO}_2\text{R}^5$, $\text{OC}_{2,6}\text{alkylSO}_2\text{R}^5$, $\text{C}_{0,6}\text{alkyl}(\text{SO}_2)\text{NR}^5\text{R}^8$, $\Theta\text{C}_{2,6}\text{alkyl}(\text{SO}_2)\text{NR}^5\text{R}^8$, $\text{C}_{0,6}\text{alkylNR}^5(\text{SO}_2)\text{R}^8$,
 $\Theta\text{C}_{2,6}\text{alkylNR}^5(\text{SO}_2)\text{R}^8$, $\text{C}_{0,6}\text{alkylNR}^5(\text{SO}_2)\text{NR}^5\text{R}^8$, $\Theta\text{C}_{2,6}\text{alkylNR}^5(\text{SO}_2)\text{NR}^5\text{R}^8$, $(\text{CO})\text{NR}^5\text{R}^8$,
 $\Theta(\text{CO})\text{NR}^5\text{R}^8$, NR^5OR^8 , $\text{C}_{0,6}\text{alkylNR}^5(\text{CO})\text{OR}^8$, $\Theta\text{C}_{2,6}\text{alkylNR}^5(\text{CO})\text{OR}^8$, SO_3R^5 and a 5- or 6-

membered ring containing atoms independently selected from the group consisting of C, N, O and S;

n is 0, 1, 2, 3, or 4; or

a pharmaceutically acceptable salt or hydrate thereof;

provided that:

a) when $X_2-X^2 = X_4-X^4 = X_5-X^5 = N$, and either of X_8-X^8 or $X_{10}-X^{10}$ is a bond, then X_9-X^9 is not N,

b) when X^7 is N at least two of X^1, X^2, X^3, X^4 , and X^5 are not N,

c) X^1 and X^3 are not O;

and provided that the compound is not:

8-[5-(3-Chloro-phenyl)-[1,2,4]oxadiazol-3-ylmethyl]-3-pyridine-4-yl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridine;

8-[5-(3-Chloro-phenyl)-[1,2,4]oxadiazol-3-ylmethyl]-3-thiophen-2-yl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridine;

~~8-[5-(5-Chloro-2-fluoro-phenyl)-[1,2,4]oxadiazol-3-ylmethyl]-3-pyridine-4-yl-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridine;~~

~~8-[5-(3-Chloro-phenyl)-[1,2,4]oxadiazol-3-ylmethyl]-3-pyridine-4-yl-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrimidine;~~

~~8-[5-(5-Chloro-2-fluoro-phenyl)-[1,2,4]oxadiazol-3-ylmethyl]-3-pyridine-4-yl-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrimidine;~~

~~8-[5-(3-Chloro-phenyl)-[1,3,4]oxadiazol-2-ylmethyl]-3-pyridine-4-yl-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrimidine;~~

~~8-[1-[5-(3-Chloro-phenyl)-[1,3,4]oxadiazol-2-yl]-ethyl]-3-pyridin-4-yl-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrimidine;~~

~~8-[5-(5-Chloro-2-fluoro-phenyl)-[1,2,4]oxadiazol-3-ylmethyl]-3-furan-2-yl-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrimidine;~~

~~8-[1-[5-(3-Chloro-phenyl)-[1,2,4]oxadiazol-3-yl]-ethyl]-3-pyridin-4-yl-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrimidine;~~

~~3-Pyridin-4-yl-8-[1-(5-m-tolyl-[1,2,4]oxadiazol-3-yl)-ethyl]-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrimidine;~~

~~(+)-8-[(1S)-1-[5-(3-chlorophenyl)-1,2,4-oxadiazol-3-yl]ethyl]-3-pyridin-4-yl-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrimidine;~~

~~(-)-8-[(1R)-1-[5-(3-chlorophenyl)-1,2,4-oxadiazol-3-yl]ethyl]-3-pyridin-4-yl-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrimidine;~~

~~3-[5-(3-Pyridin-4-yl-6,7-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrimidin-8-ylmethyl)][1,3,4]oxadiazol-2-yl]benzonitrile;~~

~~3-[5-[3-(2-Methoxypyridin-4-yl)-6,7-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrimidin-8-ylmethyl]][1,3,4]oxadiazol-2-yl]benzonitrile;~~

~~3-[5-[3-(2-Methoxy-pyridin-4-yl)-6,7-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrimidin-8-ylmethyl]-[1,2,4]oxadiazol-3-yl]benzonitrile;~~

~~3-[3-[(3-pyridin-4-yl-6,7-dihydro[1,2,4]triazolo[4,3-a]pyrimidin-8(5H)-yl)methyl]-1,2,4-oxadiazol-5-yl]benzonitrile;~~


~~3-[3-[[3-(2-methoxypyridin-4-yl)-6,7-dihydro[1,2,4]triazolo[4,3-a]pyrimidin-8(5H)-yl]methyl]-1,2,4-oxadiazol-5-yl]benzonitrile;~~

~~3-[5-[(3-pyridin-4-yl-6,7-dihydro[1,2,4]triazolo[4,3-a]pyrimidin-8(5H)-yl)methyl]-1,2,4-oxadiazol-3-yl]benzonitrile; and~~

~~3-[5-[3-(2-Hydroxy-pyridin-4-yl)-6,7-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrimidin-8-ylmethyl]-[1,2,4]oxadiazol-3-yl]benzonitrile.~~


2. (Withdrawn) The compound according to claim 1, provided that the compound is not 8-[5-(5-Chloro-phenyl)-[1,2,4]oxadiazol-3-ylmethyl]-3-furan-2-yl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrimidine,

3. (Original) The compound according to claim 1, wherein R^1 is halo, C_{1-6} alkylhalo, C_{1-6} alkyl, OC_{1-6} alkyl, or C_{0-6} alkylcyano.
4. (Original) The compound according to claim 1, wherein R^2 is hydrogen or halo.
5. (Original) The compound according to claim 1, wherein R^2 is fluorine.
6. (Original) The compound according to claim 1, of Formula II:



7. (Original) The compound according to claim 6, wherein X^7 is N.


8. **(Currently Amended)** The compound according to ~~claim 1~~ claim 1, of Formula III:




9. **(Original)** The compound according to claim 8, wherein X³ is C.

10. **(Original)** The compound according to claim 8, wherein X³ is N.

11. **(Currently Amended)** The compound according to ~~claim 1~~ claim 1, wherein the ring containing X¹, X², X³, X⁴, and X⁵ is selected from the group consisting of:




12. **(Original)** The compound according to claim 11, wherein the ring is selected from the group consisting of:



13. **(Original)** The compound according to claim 11, wherein X^7 is N.
14. **(Withdrawn)** The compound according to claim 13, wherein X^8 is a bond.
15. **(Original)** The compound according to claim 13, wherein X^8 is S.
16. **(Withdrawn)** The compound according to claim 14, wherein X^9 is CR^5 .
17. **(Withdrawn)** The compound according to claim 16, wherein X^{10} is NR^5 .
18. **(Withdrawn)** The compound according to claim 16, wherein X^{10} is O.

19. **(Withdrawn)** The compound according to claim 16, wherein X^{10} is CR^5R^6 .
20. **(Withdrawn)** The compound according to claim 16, wherein X^{10} is $(CR^5R^6)_2$.
21. **(Withdrawn)** The compound according to claim 16, wherein X^{10} is a bond.
22. **(Original)** The compound according to claim 15, wherein X^9 is CR^5 .
23. **(Original)** The compound according to claim 22, wherein X^{10} is a bond.
24. **(Withdrawn)** The compound according to claim 14, wherein X^9 is N.
25. **(Currently Amended)** The compound according to claim 11, wherein the fused ring containing X^7 , X^8 , X^9 , and X^{10} is selected from the group consisting of:



26. **(Currently Amended)** The compound according to claim 1 selected from the group consisting of: which is

7-[5-(5-Chloro-2-fluorophenyl)-1,2,4-oxadiazol-3-yl]-3-(2-thienyl)-6,7-dihydro-5H-[1,2,4]triazolo[3,4-b][1,3]thiazine,

9-[[5-(3-chlorophenyl)-1,2,4-oxadiazol-3-yl]methyl]-3-pyridin-4-yl-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a][1,3]diazepine,

9-[1-[5-(3-chlorophenyl)-1,2,4-oxadiazol-3-yl]ethyl]-3-pyridin-4-yl-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a][1,3]diazepine,

7-[[5-(3-chlorophenyl)-1,2,4-oxadiazol-3-yl]methyl]-3-pyridin-4-yl-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazole,

9-[[5-(3-chlorophenyl)-1,2,4-oxadiazol-3-yl]methyl]-3-(trifluoromethyl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a][1,3]diazepine,

8-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-3-(4-methoxy-phenyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine,

8-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-3-(4-methoxy-phenyl)-7-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine,

9-[[5-(3-chlorophenyl)isoxazol-3-yl]methyl]-3-(3,5-difluorophenyl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a][1,3]diazepine,

~~9-[[5-(3-chlorophenyl)isoxazol-3-yl]methyl]-3-(4-methoxyphenyl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a][1,3]diazepine,~~
~~9-[[5-(3-chlorophenyl)isoxazol-3-yl]methyl]-3-pyridin-4-yl-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a][1,3]diazepine,~~
~~9-[[5-(5-chloro-2-fluorophenyl)-1,2,4-oxadiazol-3-yl]methyl]-3-pyridin-4-yl-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a][1,3]diazepine,~~
~~9-[[5-(3-chlorophenyl)-1,2,4-oxadiazol-3-yl]methyl]-3-(3,5-difluorophenyl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a][1,3]diazepine,~~
~~9-[[5-(3-chlorophenyl)-1,2,4-oxadiazol-3-yl]methyl]-3-(4-methoxyphenyl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a][1,3]diazepine, and~~

pharmaceutically acceptable salts thereof.

27. **(Currently Amended)** A pharmaceutical composition comprising as active ingredient a therapeutically effective amount of the compound according to any one of claims 1, 3-13, 15, 22, 23, 25 and 26, and one or more pharmaceutically acceptable diluents, excipients, and/or inert carriers.

28. **(Canceled)**

29. (Canceled)

30. (Canceled)

31. (Canceled)

32. (Canceled)

33. (Currently Amended) The method according to any one of claims 32, 35, 36 and 37, wherein the mammal is a human.

34. (Canceled)

35. (Currently Amended) ~~The A method for the treatment of according to claim 32,~~
~~wherein the disorder is a psychiatric disorder comprising administering to a mammal in need~~
thereof a therapeutically effective amount of the compound according to claim 1.

36. (Currently Amended) ~~The A method for the treatment of according to claim 32,~~
~~wherein the disorders are selected from chronic and acute pain disorders comprising~~

administering to a mammal in need thereof a therapeutically effective amount of the compound according to claim 1.

37. **(Currently Amended)** ~~The~~ A method for the treatment of gastro-esophageal reflux disorder (GERD) comprising administering to a mammal in need thereof a therapeutically effective amount of the compound according to claim 1~~according to claim 32, wherein the disorder is a gastrointestinal disorder.~~

38. **(Canceled)**